Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conf

Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenviron

Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-

Gainers NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 56.7% to $0.16 during Friday's pre

CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clini

 Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels

Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday'

Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market

Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cel

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experi

ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induc

President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Manag

Video webcast now available  here

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 year

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-1

Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical stud

Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead o

US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while heal

Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's

Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the tre

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Signi

CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune

New platform provides additional perspective on Ernexa's mission to deliver hope for patients throug

Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the tre

Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical O

Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engin

Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the tre

CAMBRIDGE, Mass. , May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renew

US stocks lower, Nasdaq down 1% on Tuesday. Health care shares rise 1.7%. Inflation climbs to 3.8%,

Brookline Capital initiates coverage on Ernexa Therapeutics (NASDAQ:ERNA) with a Buy rating and an

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announ

Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the tre

The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price req